{"id":"ag-881","safety":{"commonSideEffects":[{"rate":"30%","effect":"Fatigue"},{"rate":"20%","effect":"Nausea"},{"rate":"15%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AG-881 is a potent and selective inhibitor of TET2, a key enzyme involved in DNA demethylation. Inhibition of TET2 has been shown to induce DNA hypermethylation and suppress cancer cell growth.","oneSentence":"Tet methylcytosine dioxygenase 2 (TET2) inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T05:50:18.114Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML)"}]},"trialDetails":[{"nctId":"NCT05484622","phase":"PHASE1","title":"Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut de Recherches Internationales Servier","startDate":"2023-01-20","conditions":"Astrocytoma, Oligodendroglioma","enrollment":60},{"nctId":"NCT02481154","phase":"PHASE1","title":"Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2015-06","conditions":"Glioma","enrollment":95},{"nctId":"NCT03343197","phase":"PHASE1","title":"Study of AG-120 and AG-881 in Subjects With Low Grade Glioma","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2018-03-20","conditions":"Glioma","enrollment":49},{"nctId":"NCT06780930","phase":"PHASE3","title":"Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Servier","startDate":"2024-10-18","conditions":"Residual or Recurrent Grade 2 IDH Mutant Glioma","enrollment":57},{"nctId":"NCT04603001","phase":"PHASE1","title":"Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2020-11-19","conditions":"Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML)","enrollment":260},{"nctId":"NCT04164901","phase":"PHASE3","title":"Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut de Recherches Internationales Servier","startDate":"2020-01-05","conditions":"Grade 2 Glioma, Residual Glioma, Recurrent Glioma","enrollment":331},{"nctId":"NCT05592743","phase":"","title":"Vorasidenib Expanded Access Program","status":"APPROVED_FOR_MARKETING","sponsor":"Servier","startDate":"","conditions":"Glioma, Recurrence, Disease Attributes","enrollment":""},{"nctId":"NCT05674474","phase":"PHASE1","title":"A Study of Vorasidenib in Participants With Moderate or Mild Hepatic Impairment and Matched Participants With Normal Hepatic Function","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2023-03-14","conditions":"Hepatic Impairment","enrollment":16},{"nctId":"NCT04128787","phase":"PHASE1","title":"A Study to Compare the Relative Bioavailability of Two AG-881 Formulations and Evaluate the Effect of Food and Omeprazole on the Pharmacokinetics of AG-881","status":"COMPLETED","sponsor":"Agios Pharmaceuticals, Inc.","startDate":"2019-09-30","conditions":"Healthy Volunteers","enrollment":36},{"nctId":"NCT04145128","phase":"PHASE1","title":"A Study to Evaluate AG-881 in Healthy Japanese and Non-Asian Participants","status":"COMPLETED","sponsor":"Agios Pharmaceuticals, Inc.","startDate":"2019-10-02","conditions":"Healthy Volunteers","enrollment":32},{"nctId":"NCT03960502","phase":"PHASE1","title":"A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C] AG-881 and Concomitant Intravenous Microdose of [13C315N3] AG-881","status":"COMPLETED","sponsor":"Agios Pharmaceuticals, Inc.","startDate":"2019-05-16","conditions":"Healthy Male Participants","enrollment":5},{"nctId":"NCT04015687","phase":"PHASE1","title":"A Study to Evaluate the Effect of AG-881 on the Pharmacokinetics of a Single Dose of Lamotrigine in Healthy Adults","status":"COMPLETED","sponsor":"Agios Pharmaceuticals, Inc.","startDate":"2019-07-15","conditions":"Healthy Participants","enrollment":22},{"nctId":"NCT02492737","phase":"PHASE1","title":"Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation","status":"COMPLETED","sponsor":"Agios Pharmaceuticals, Inc.","startDate":"2015-08-07","conditions":"Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, Hematologic Malignancies","enrollment":46}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"AG-881","genericName":"AG-881","companyName":"Agios Pharmaceuticals, Inc.","companyId":"agios-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tet methylcytosine dioxygenase 2 (TET2) inhibitor Used for Acute myeloid leukemia (AML).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}